F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm

Melanoma Research

Volumn 17, Issue 3, 2007, Pages 147-154

  Maubec, Eve ^a,b   Lumbroso, Jean ^a   Masson, Florence ^a,c   Suciu, Voichita ^a   Kolb, Frédéric ^a   Mamelle, Gérard ^a   Cavalcanti, Andrea ^a   Boitier, Françoise ^a   Spatz, Alain ^a   Aupérin, Anne ^a   Leboulleux, Sophie ^a   Avril, Marie Françoise ^a,d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b BICHAT HOSPITAL   (France)

^c INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE IRSN   (France)

^d Paris V University ^*  (France)

Author keywords

Fluorodeoxyglucose; Melanoma; Positron emission tomography; Sentinel lymph node biopsy; Tumor staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CYTODIAGNOSIS; CANCER SIZE; CANCER STAGING; CERVICAL LYMPH NODE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; FALSE POSITIVE RESULT; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MALE; MELANOMA; MICROMETASTASIS; NON INVASIVE MEASUREMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; SKIN METASTASIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 34249076712     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32815c10b0     Document Type: Article

References (23)

1. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
2. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392-399.
3. Essner R, Chung MH, Bleicher R, Hsueh E,Wanek L, Morton DL. Prognostic implications of thick (> or = 4-mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol 2002; 9:754-761.
4. Balch CM, Cascinelli N, Sim FH, Soong SJ, Taylor WF, Bufalino R. Elective lymph node dissection: results of prospective randomized surgical trials. In: Balch CM, Houghton AN, Sober AJ, Soong SJ, editors. Cutaneous melanoma. 3rd ed. QMP; USA. 1998. pp. 209-225.
5. Cook MG, Green MA, Anderson B, Eggermont AM, Ruiter DJ, Spatz A, et al., EORTC Melanoma Group. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol 2003; 200:314-319.
6. Clark PB, Soo V, Kraas J, Shen P, Levine EA. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg 2006; 141:284-288.
7. Makosz T, Assaf C, Georgieva J, Orfanos CE, Geilen CC. Detection of malignant melanoma in a giant congenital naevocytic naevus by positron emission tomography. Br J Dermatol 2004; 151:724-726.
8. Vandewoude M, Cornelis A, Wyndaele D, Brussaard C, Kums R. (18)FDG-PET-scan in staging of primary malignant melanoma of the oesophagus: a case report. Acta Gastroenterol Belg 2006; 69: 12-14.
9. Wagner JD, Schauwecker D, Davidson D, Logan T, Coleman JJ III, Hutchins G, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 2005; 104:570-579.
10. Blessing C, Feine U, Geiger L, Carl M, Rassner G, Fierlbeck G. Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol 1995; 131:1394-1398.
11. Wagner JD, Schauwecker D, Hutchins G, Coleman JJ III. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 1997; 64:181-189.
12. Crippa F, Leutner M, Belli F, Gallino F, Greco M, Pilotti S, Cascinelli N, et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 2000; 41:1491-1494.
13. Wagner JD, Schauwecker DS, Davidson D,Wenck S, Jung SH, Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 2001; 77:237-242.
14. Kokoska MS, Olson G, Kelemen PR, Fosko S, Dunphy F, Lowe VJ, et al. The use of lymphoscintigraphy and PET in the management of head and neck melanoma. Otolaryngol Head Neck Surg 2001; 125:213-220.
15. Acland KM, Healy C, Calonje E, O'Doherty M, Nunan T, Page C, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 2001; 19:2674-2678.
16. Belhocine T, Pierard G, De Labrassinne M, Lahaye T, Rigo P. Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection. Oncologist 2002; 7:271-278.
17. Fink AM, Holle-Robatsch S, Herzog N, Mirzaei S, Rappersberger K, Lilgenau N, et al. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res 2004; 14:141-145.
18. Vereecken P, Laporte M, Petein M, Steels E, Heenen M. Evaluation of extensive initial staging procedure in intermediate/high-risk melanoma patients. J Eur Acad Dermatol Venereol 2005; 19:66-73.
19. Macfarlane DJ, Sondak V, Johnson T, Wahl RL. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 1998; 16:1770-1776.
20. Rinne D, Baum RP, Hor G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998; 82:1664-1671.
21. Mijnhout GS, Hoekstra OS, van Lingen A, van Diest PJ, Ader HJ, Lammertsma AA, et al. How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning: the case of lymph node staging in melanoma. J Clin Pathol 2003; 56:283-286.
22. Buzaid AC, Sandler AB, Mani S, Curtis AM, PooWJ, Bolognia JL, et al. Role of computed tomography in the staging of primary melanoma. J Clin Oncol 1993; 11:638-643.
23. Miranda EP, Gertner M, Wall J, Grace E, Kashani-Sabet M, Allen R, et al. Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg 2004; 139:831-836; discussion 836-837.